Tag: ACC
Class of 2024–25: VQI announces third annual set of Fellowship in...
The Vascular Quality Initiative (VQI) Patient Safety Organization’s Fellowship in Training (FIT) Program has announced its third class of FIT participants for 2024–25 alongside...
From the editor: House of Cards
On Jan. 22, 2024, the American Heart Association (AHA) and the American College of Cardiology (ACC), together with three other major cardiology societies, submitted...
PAD guideline update from ACC, AHA and others centers multispecialty care
New multisociety clinical practice guidelines for the management of lower extremity peripheral arterial disease (PAD) have been published online in the Journal of the...
SCAI issues position paper on transaxillary arterial access
The Society for Cardiovascular Angiography & Interventions (SCAI) has released an official position statement providing evidence-based recommendations for percutaneous transaxillary arterial access and training...
ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in...
Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease...
SVS, ACC complete move to single vascular registry
The Society for Vascular Surgery (SVS) and the American College of Cardiology (ACC) have completed a move to create a single vascular registry.
The new...
‘Ample published data unable to replicate association between paclitaxel-coated devices and...
Ample published data from from large, observational datasets, randomized-controlled trial (RCT) subgroup analyses and long-term follow-up from pivotal paclitaxel-coated device RCTs have not been...
ACC, SVS join forces on single vascular registry
The American College of Cardiology (ACC) and Society for Vascular Surgery (SVS) are collaborating on a single vascular registry to harness the strengths of...
Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization
Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of...